
ProteomeScout™ technology enables the quantitative proteomic profiling of thousands of samples with unprecedented accuracy, precision, and depth (up to >10,000 proteins). Our automated 96-well plate workflow leverages data-independent acquisition (DIA) for label-free analysis and is readily scalable, allowing hundreds to thousands of compounds to be screened quickly and accurately. As a result, projects can often proceed from treated cells to reported data in less than two weeks, matching medchem development cycles and accelerating drug discovery efforts. These high-throughput capabilities facilitate rapid proteome-wide selectivity profiling for fast drug optimization iterations, provide valuable selectivity data early in compound development, and save significant time in the development of targeted protein degraders.

